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Graphical abstract 
 
 
Highlights 
 Electrospun nanofibers of indomethacin were prepared 
 Full factorial design was used for statistical optimization 
 Dissolution of  drug nanofibers can be modified using different polymers 
 Optimum formulation exhibited appropriate drug release as a colon delivery system 
 
Abstract 
Generally, although the conventional drug delivery systems, such as using only pH-
dependent polymers or time-dependent release systems are popular, the individuals’ 
variations of physiological conditions usually lead to premature or imperfect drug release 
from each of these systems. Therefore, a combination of pH- and time-dependent polymers 
could be more reliable for delivering drugs to the lower GI tract such as colon. To this end, 
electrospinning method was used as a fabrication approach for preparing electrospun 
nanofibers of indomethacin aimed for colon delivery. Formulations were prepared based on a 
32 full factorial design. Independent variables were the drug:polymer ratio (with the levels of 
3:5, 4.5:5 and 6:5 w/w) and Eudragit S:Eudragit RS w/w ratio (20:80, 60:40 and 100:0). The 
evaluated responses were drug release at pH 1.2, 6.4, 6.8 and 7.4. Combinations of Eudragit S 
(ES), Eudragit RS (ERS) and drug based on factorial design were loaded in 10 ml syringes. 
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Electrospinning method was used to prepare electrospun nanofibers from electrospinning 
solutions. Conductivity and the viscosity of the solutions were analyzed prior to 
electrospinning. After collection, the nanofibers were evaluated in terms of morphology and 
drug release. It was shown that the ratio of drug:polymer and polymer:polymer were pivotal 
factors to control the drug release from nanofibers. A formulation containing Eudragit 
S:Eudragit RS (60:40) and drug:polymer ratio of 3:5 exhibited the most appropriate drug 
release as a colon delivery system with a minor release at pH 1.2, 6.4 and 6.8 and major 
release at pH 7.4. Nanofibers resulted from this formulation were also more uniform and 
contained fewer amounts of beads. It was demonstrated that the electrospinning could be 
regarded as a modern approach for the preparation of colon drug delivery systems leading to 
marketable products. 
 
Keywords: Colon delivery; Electrospinning; Nanofiber; Eudragit; Indomethacin, Release rate. 
 
1. Introduction 
In recent years, various methods have been examined for oral drug delivery to the colon. 
Among those techniques regarding drug delivery to the colon, pH-dependent and time-
dependent drug delivery systems are popular [1]. Despite the popularity of the above drug 
delivery systems, it should be mentioned that individual variations of physiological 
conditions usually lead to premature or imperfect drug release from each of these systems [2]. 
Therefore, a combination of pH- and time-dependent polymers could be more reliable for 
delivering drugs to the lower GI tract and preferably to the terminal ileum and the first part of 
the colon which are the predominate sites of inflammation in colon diseases such as Crohn’s 
disease or ulcerative colitis [3].  
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Nowadays, nanofibers with diameters in the nanometer range have gained attention due to 
remarkable characteristics such as high porosity and large surface area to volume ratio which 
mostly improves the function of the incorporated materials [4, 5]. As a consequence, the 
application of these materials in biomedical usages such as tissue engineering [6, 7], wound 
dressing [8], and enzyme immobilization [9] has been widespread. Nanofibers have been 
used as drug carriers in the drug delivery system due to their high functional characteristics. 
Different controlled drug release profiles, such as immediate, sustained, and biphasic releases 
could be achieved by electrospun nanofibers. Moreover, fabrication of nanofibers using 
electrospinning is a simple and straight forward process. Polymer nanofibers with a wide 
range in size can be manufactured using electrospinning. The nanofibers have other 
remarkable characteristics such as high porosity and large surface area to volume ratio which 
mostly improves the function of the incorporated materials. Also, fibers have high 
encapsulation efficiency as there is no loss during the preparation [10-17].  
In electrospinning, the induction of an electric charge in the surface of a polymeric solution 
gives an electric charge to the liquid. By extruding this charged polymeric solution through a 
nozzle the droplets of the solution are elongated by the electrostatic force operating between 
droplet and substrate. The nanofiber is formed by solvent evaporation from the droplet and 
the fabricated fibers can be collected in the collector plate [18-20].  
Certain studies have been accomplished to produce an oral drug delivery system based on 
electrospun nanofibers [21-23]. Nevertheless, very limited work has been published on the 
application of these nano scale fibers in colonic drug delivery. In a study, Eudragit L 100-55 
nanofibers containing diclofenac sodium were fabricated by electrospinning and they showed 
that nanofibers had a pH-dependent drug release profile and therefore have the potential as a 
colonic drug delivery system for diclofenac [24]. Similar results have been found for 
diclofenac-loaded Eudragit L100 nanofibers produced by a modified coaxial electrospinning 
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technology [25]. In addition, shellac nanofibers loaded with ferulic acid has been prepared in 
another investigation using a coaxial electrospinning process for colon delivery [26].  
A colon drug delivery system using core/shell fibers prepared with Eudragit S100 and ethyl 
cellulose has already been reported [27] where, ethyl cellulose was used as a sustained 
release polymer in the core of nanofibers while Eudragit S as a pH-dependent polymer was in 
the shell. To best of our knowledge, the combination of pH- and time-dependent systems in 
the matrix of nanofibers has not been explored for colon delivery. Therefore, in the present 
study, electrospun nanofibers were fabricated using a combination of two different 
approaches i.e. pH- and time-dependent systems in the matrix of nanofibers providing a 
colon-specific drug delivery system. Eudragit S100 and Eudragit RS100 were used as pH-
dependent and time-dependent polymers, respectively. Indomethacin was used as a model 
drug due to its potential treatment for colon cancer [28, 29].  
 
2. Materials and methods 
2.1 Materials 
Indomethacin (Darupakhsh, Iran), Eudragit RS100 (ERS)(Rohm Pharma, Germany), Eudragit 
S100 (ES)(Rohm Pharma, Germany), KH2PO4 (Merck, Germany), NaOH (Merck, Germany), 
and hydrochloric acid (Merck, Germany) were obtained from the indicated sources.  
 
2.2 Experimental design 
A 32 full factorial design was used for the design of formulations. Independent variables were 
the ratio of Eudragit S: Eudragit RS (with the levels of 20:80, 60:40 and 100:0 w/w)(X1) and 
drug:polymer ratio (with the levels of 3:5, 4.5:5 and 6:5 w/w)(X2). Dependent variables 
(responses) were as follows: 
6 
 
 Y1: drug release at pH 1.2 for 2 h; Y2: release at pH 6.4 for 1 h; Y3: release at pH 6.8 for 2 h; 
and Y4: release at pH 7.4 for 2 h. Although, the dissolution at pH 1.2 was performed for 4 h 
and in other pHs for 10 h, the selected dissolution times in the experimental design were on 
the basis of the residence time of particles in the GI tract.  Table 1 depicts compositions of 
experimental formulations.  
 
2.3 Preparation of spinning solutions 
Solutions of a combination of ERS and ES (2.5% w/v) were prepared in ethanol as a good 
solvent. Separately, indomethacin (1.5% w/v) solution was prepared in ethanol. Afterward, 
the solutions were mixed with each other. The ratios of ES:ERS and drug:polymer solution 
were based on the full factorial design described earlier in the manuscript.   
2.4 Characterization of spinning solutions 
Prior to electrospinning, the conductivity (measured by a conductivity meter,8301, AZ 
Instrument Corp., Taiwan) and viscosity (measured by Brookfield viscometer, R?S plus, 
Germany) of the prepared solutions were measured.  The rheometer was equipped with a 
cone/plate accessory (spindle type CC3-25) which was used at a constant shear rate of 100 
sec−1 to measure the viscosity of the solutions at room temperature. 
 
2.5 Electrospinning process 
Electrospinning solutions containing different ratios of drug:polymers were loaded in 10 ml 
syringes. The feeding rate was controlled by a syringe pump (Cole-Pham®, USA) and was 
fixed at 2.0 mL/h. A high voltage supply fixed at 10-18 kV was applied, and a piece of 
aluminum foil was used to collect the ultrafine fibers with a horizontal distance of 15 cm 
from the needle tip. Electrospun nanofibers were collected and stored in a desiccator for 
further studies. 
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2.6 Scanning electron microscopy (SEM) 
The surface morphologies of electrospun nanofibers were assessed using a scanning electron 
microscope (LEO-rp-1455). The samples were previously silver sputter-coated under argon 
to render them electrically conductive. The pictures were then taken at an excitation voltage 
of 15 kV. 
 
2.7 In vitro dissolution studies 
Dissolution studies were carried out by introducing a certain amount of each nanofiber 
formulation equivalent to 10 mg of indomethacin in the dissolution baskets (DT800, Erweka, 
Germany; USP apparatus I) at 37°C with a rotation speed of 100 rpm  (100 mL of dissolution 
medium; n=3). The method was modified in a way that a smaller flask (500 ml) was set 
inside the main dissolution flasks, so that, the baskets could reach the bottom of the vessels 
containing 100 ml of the dissolution media. Dissolution tests were performed in 0.1 N HCl at 
pH 1.2 for 4 h. The dissolution of samples was also performed at different pHs (6.4, 6.8 and 
7.4) for 10 h. At predetermined time intervals, aliquots of 1 mL were withdrawn for sampling 
and replaced by an equal volume of fresh dissolution medium to maintain a constant volume. 
Afterward, the sample solutions were assayed spectrophotometrically by a UV/Visible 
spectrophotometer (Biowave II, WPA, England) at a wavelength of 320 nm. A calibration 
curve was constructed and validated to measure the concentration of the samples. In case of 
high concentrations of the drug in the sample, dilution was made to reach the absorbance 
within the calibration curve set up. 
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2.8 Statistical analysis of data 
The effects of the independent variables on each experimental response were modeled using a 
second-order polynomial equation: 
Y = C + b1X1 + b2X2 + b3X1
2 + b4X2
2 + b5X1X2                               Eq. 1 
X1 is the ratio of polymer 1:polymer 2 and X2 is the ratio of drug:polymer. Models were 
simplified with a backward, stepwise linear regression technique. Only significant terms (P < 
0.05) were chosen for the final model. Modeling was performed using SPSS (version 15.0). 
Response surface plots and contour plots resulting from equations were obtained by 
Statgraphics XVI. 
3. Results and discussion 
3.1 Fiber morphology 
Based on our preliminary experiments, ethanol was chosen as a solvent for dissolving both 
ERS and ES. Also, the selection of various ratios of polymers to the drug was according to 
preformulation studies published elsewhere [30]. 
Scanning electron micrographs of drug-loaded nanofibers F1-F3 (Figure 1) showed that the 
increase in drug level in the composition of the formulations modified the morphology of 
nanofibers. For instance, formulation F3 with the high level of the drug showed some beads 
in its SEM image (Figure 1c). The changes in the morphology of nanofibers at high drug 
concentration was supported by previous studies [31, 32]. It has been reported that these 
changes in the morphology could be due to a reduction in the polymer solution viscosity 
following the addition of drug. This reduction can, in turn, increase the surface tension which 
leads to the morphology changes and the appearance of beads [33-34]. However, in the 
present study, the viscosity of spinning solutions did not show a significant decrease in 
viscosity when the level of drug was increased (Table 2). This may be due to having 
relatively low viscosity for the solution as a result of the low concentration of polymers used 
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in the formulations. Meanwhile, according to the results of the conductivity of the solutions 
(Table 2), the conductivity was lower in the solutions containing high amounts of the drug. 
The solution conductivity is a main effective parameter in the electrospinning method. In 
fact, repulsion of the charges on the surface of the droplet of the polymer solution is a key 
factor in stretching solution and the production of a uniform electrospun nanofiber. 
Therefore, higher solution conductivity creates more charge and subsequently bead-free 
uniform nanofibers [35]. This could be the main reason for the formation of more uniform 
fibers at a low concentration of the drug in the formulations compared to when a high 
concentration of indomethacin used.  
According to SEM results (Fig. 1) formulation F1 produced nanofibers with some beads 
despite the highest degree of conductivity. This could be attributed to the high viscosity of 
this formulation compared with the other solutions (Table 2). When the viscosity of the 
solution gets high the formation of suitable nanofibers with acceptable characteristics is 
difficult. In another study focused on the effect of physical characteristics of poly (vinyl 
alcohol) solutions on nanofiber formation, Rosic et al., revealed that the effect of viscosity on 
the fiber structure and the shape of beads is relative and above a specific grade of viscosity, 
the effect would be inverted [36].  
Nanofibers containing ES:ERS with the ratio of 60:40 (F4-F6) showed a uniform and smooth 
morphology in all ratios of drug:polymer (Fig. 1). This finding confirmed that a combination 
of ES and ERS in this ratio would be optimum for the preparation of favorable electrospun 
nanofibers.     
 
3.2 In vitro release study 
In vitro dissolutions were carried out in dissolution media with pH 1.2, 6.4, 6.8 and 7.4 to 
mimic various parts of the gastrointestinal tract. The drug release profiles of nanofibers in the 
10 
 
acid medium with pH 1.2 are shown in Figure 2A. As can be seen from Figure 2A, the drug 
release rate in the acid medium was very slow, with no more than 5% of the incorporated 
drug released from all the formulations within the first 2 h. Of all the electrospun nanofibers, 
formulations containing ES exhibited more resistance to drug release in the acidic media. For 
example, F7 containing 100% ES and the drug:polymer ratio of 3:5 showed the least drug 
release (less than 1% within 2 h) which can be ignored. It was also interesting to note that, 
although, in formulations F1-F3 the amount of ES was lower than the other nanofibers (1:4 
relative to ERS) they still showed a low amount of drug released in acidic condition (less than 
5% drug release). In fact, the presence of ES in the nanofiber structure even at the low levels 
caused drug protection in the simulated gastric medium. This finding was in agreemnt with 
the other investigations [37, 38] in which ES prevented drug release in acidic pH from 
electrospun nanofibers comprising pantoprazole and budesonide. In another study working on 
5-fluorouracil (5-FU) loaded fibers with ES shell, a rapid release in the acidic medium was 
reported and explained by the high acid solubility of the drug and also the low molecular 
weight of 5-FU which enabled drug diffusion through the pores in the polymer coating [39]. 
Meanwhile, as pKa of indomethacin is 4.5, therefore, it is expected that its solubility should 
be low in acidic condition. On the basis of this fact, the protective effect of ES at pH 1.2 was 
the main factor for small drug release.     
Drug release from all the formulations in the buffer medium (pH 6.4) was higher than the 
release in the acid medium (Figure 2B). This may be partly due to the better solubility of 
indomethacin at pH 6.4. Meanwhile, according to Figure 2B, formulations F8 and F9 showed 
unexpected highest drug release among the nanofibers despite the presence of ES in their 
compositions. The result showed that the presence of ERS in the structure of nanofiber is 
necessary to achieve a sustained drug release profile. Compositions of F8 and F9 include ES 
and drug in the ratios of 5:4.5 and 5:6, respectively. In this regard, the matrix formation of 
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pH-dependent polymer is incomplete and subsequently higher drug release from electrospun 
nanofibers will be expected compared to the nanofibers comprising ERS. This could be the 
reason for smaller drug release from F7 (the lower level of indomethacin in the formulation) 
compared to the two mentioned formulations. Moreover, as our previous investigation 
demonstrated, the inclusion of the drug in the nanofiber structure especially in formulations 
containing ERS caused a reduction in glass transition temperature of Eudragits [30] which in 
turn could complete the formation of polymeric matrix. According to Figure 2B, F4 
comprising ES:ERS in the ratio of 60:40 and the high ratio of polymer:drug exhibited the 
lowest drug release at pH 6.4.    
The in vitro release studies at pH 6.8 were approximately the same as the release at pH 6.4 
(Figure 3A). As shown in Figure 3A, the highest drug release belonged to formulations 
containing ES alone (especially F8 and F9) whereas the addition of ERS up to 40% 
diminished the drug release at pH 6.8 in such a way that nanofibers of formulation F4 
released the drug in the slowest manner.  
Meanwhile, the drug release from formulations at pH 7.4 was dependent on the presence of 
ES (Figure 3B). As can be seen in Figure 3B, regardless of the amount of drug, fibers 
containing higher levels of ES exhibited faster drug release at pH 7.4. 
Figure 4 depicts response surface plots for all the responses. Accordingly, drug release at pH 
6.4 as well as pH 6.8 was dependent on the ratio of ES:ERS. Up to a specific ratio of ES:ERS 
(60% at pH 6.4 and 40% at pH 6.8) the increase in the level of ES resulted in a decrease in 
the drug release. However, the higher amounts of ES in the formulations enhanced drug 
release from nanofibers. This could be due to the presence of a more uniform structure of 
nanofibers containing higher levels of ERS which confirmed by SEM results (Fig. 1) and it 
may be the outcome of the complete polymeric matrix formation in the specific proportions 
of the two types of Eudragits, as mentioned before. Regarding the pH-independency of ERS 
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and low solubility of ES at pH values less than 7.0, the formation of matrix chains prevented 
a quick movement of the dissolution medium through the polymeric chains and thereupon 
delayed drug release from electrospun fibers. Nevertheless, considering a complete 
dissolution of ES at pH 7.4, the drug release was entirely dependent on the amount of ES in 
the formulation and with the increase of ES:ERS ratio, the release of indomethacin from 
nanofibers was amplified (Fig. 6).              
 
3.3 Kinetics of drug release from nanofibers  
The mechanism of release of indomethacin from fibers was evaluated by analyzing the drug 
release profiles using the zero-order, Higuchi, and Peppas models. According to Table S1 
(see supplementary materials), the drug release at pH 6.4 was fitted well to Higuchi model 
(R2 > 0.955 for all formulations). Therefore, the drug release occurred via diffusion-
controlled mechanism at pH 6.4 [40, 41]. This can be explained by the insoluble 
characteristics of Eudragits at pH 6.4. At pH 6.8, the mechanism of drug release from fibers 
containing ERS except F4 was also fitted well to Higuchi model. However, the best fit for 
drug release from formulations F4, F7, F8 and F9 was found to be Peppas model (Q = ktn) 
with the diffusion exponent n equal to 0.9842, 0.5019, 0.8305, and 0.8416, respectively. 
Hence, the values of n for these nanofibers fell between 0.5 and 1, indicating that non-Fickian 
diffusion mechanism may control the drug release i.e. release from the nanofibers was 
controlled via a combination of diffusion and erosion mechanisms [42]. Taking into account 
the presence of ES in the structure of mentioned fibers and the higher value of pH, some parts 
of the polymeric matrix could be erodible and therefore, the mechanism of erosion could also 
contribute to the drug release. Analyzing the drug release profiles at pH 7.4 verified this fact. 
Accordingly, the drug release from all the nanofibers at pH 7.4 was fitted to Peppas model. 
The value of n for all the formulations was more than 0.5 except F1 and F2 which their n 
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values were 0.4104 and 0.3308, respectively, indicating that diffusion was a prominent 
mechanism of drug release from the two latter nanofibers.                      
 
3.4 Optimization 
Mathematical relationships were generated between the dependent and independent variables 
using the statistical package SPSS. The resulted second order polynomial equations for all of 
the responses are given below: 
 
Y1 = 4.562 - 0.0003X1X1                                                                                                                                          Eq. 2 
Y2 = -11.352 - 0.858X1+ 93.69X2 + 0.004X1X1 – 60.432X2X2 + 0.499X1X2           Eq. 3  
Y3 = -58.353 – 2.245X1 + 303.014X2 + 0.019X1X1 – 181.481X2X2 + 0.681X1X2   Eq. 4  
Y4 = -76.871 + 0.648X1 + 272.986X2 – 0.005X1X1 – 171.914X2X2 + 0.705X1X2   Eq. 5  
The three-dimensional response surface plots and contour plots resulted from the above 
equations were drawn to find the best area for optimum formulation. 
Optimization is one of the main objectives of using an experimental design for the production 
of formulations. To achieve a suitable optimization process the selection of the effective 
responses is the essential parameter. Since pH and the residence time of different parts of GI 
tract are substantial factors for the design of a colonic delivery system, they should be 
regarded as the main responses. All of the manufactured nanofibers showed minimum drug 
release and therefore optimum characteristics in the acid media. According to the relative 
constant residence time of materials in the small intestine [43] and the pH gradient of this part 
of GI tract, the residence time for dissolution media with pH 6.4, pH 6.8 and pH 7.4 were 
considered 1, 2 and 2 h, respectively. Drug release less than 5%, 10% and 20% was 
considered as optimum release at pH 1.2, 6.4 and 6.8, respectively. On the other hand, taking 
into account the fact that a colon delivery system based on pH- and time-dependent polymers 
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should release majority of the drug at the terminal ileum, and the authors believed that 2/3 of 
drug release which is around 65% could be as an indication of a good drug release in that 
region. It also ensures that the drug release is occurring. Therefore, the drug release more 
than 65% was considered as the best constraint at pH 7.4.  
 
According to contour plots (Fig. S1) formulation containing ES:ERS (60:40) and 
drug:polymer ratio of 3:5 (F4) theoretically met the criteria for all the optimum responses. In 
order to check the validity of the process of optimization, a new batch of nanofibers with the 
predicted levels of independent variables was prepared and examined. The results in Table S2 
showed that the observed responses were close to the predicted responses, and therefore the 
validation of experimental design for predicting the optimum formulation was confirmed. 
Therefore, as an overall consequence, nanofibers containing ES:ERS (60:40) and 
drug:polymer ratio of 3:5 exhibited the optimum drug release at various parts of GI tract with 
different pHs. This kind of nanofibers have the potential to release the major contents of the 
drug in the proximal colon. 
 Although, the scale up of the electrospinning technology might be a challenge 
for the pharmaceutical industry because of the low production rate of fibers [44], 
therefore, various attempts have been made to enhance the productivity of this 
technique. Recently, different processes such as multiple-jet electrospinning [45, 46], 
high speed electrospinning [47], edge electrospinning [48] and needleless electrospinning 
[49] have been developed. Also, downstream processing of nanofibers to produce tablet 
formulations from electrospun solid dispersions has been investigated [50]. The present 
study aimed to optimize the formulation to improve the potential for this technology to 
be scaled up for commercialization purpose. 
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4. Conclusion 
According to the results of this study, electrospinning was an appropriate method for 
producing nanofibers of indomethacin aimed for colonic drug delivery. It was shown that 
selecting an appropriate experimental design and optimization technique can be successfully 
applied to the development of nanofibers based on Eudragit polymers to achieve colon drug 
delivery. According to optimization process, a formulation containing ES:ERS (60:40) and 
drug:polymer ratio of 3:5 exhibited suitable morphological characteristics and protected a 
major part of drug in the media simulating upper GI tract and therefore could be good 
excipients as a colonic drug delivery system for indomethacin. 
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Figure 1. SEM images of formulations; (a) F1, (b) F2, (c) F3, (d) F4, (e) F5, (f) F6, (g) F7, (h) 
F8, and (i) F9. 
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Figure 2. Dissolution profiles of formulations at (A) pH 1.2 and (B) pH 6.4 (n=3; error bars 
are standard deviation). 
  
21 
 
 
Figure 3. Dissolution profiles of formulations at (A) pH 6.8 and (B) at pH 7.4 (n=3; error bars 
are standard deviation). 
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Figure 4. Response surface plots; (a) Y2, (b) Y3, and (c) Y4. 
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Table 1. Composition of experimental formulations 
 
Variable factors Components of nanofibers 
 X1(ES:ERS ratio) X2 (drug:polymer ratio) Eudragit S (%) Eudragit RS (%) Indomethacin (%) 
F1 20:80 3:5 12.5 50 37.5 
F2 20:80 4.5:5 10.5 42.5 47 
F3 20:80 6:5 9 36.5 54.5 
F4 60:40 3:5 37.5 25 37.5 
F5 60:40 4.5:5 32 21 47 
F6 60:40 6:5 27.5 18 54.5 
F7 100:0 3:5 62.5 0 37.5 
F8 100:0 4.5:5 53 0 47 
F9 100:0 6:5 45.5 0 54.5 
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Table 2. Conductivity and viscosity of spinning solutions used for preparation of 
formulations (values are the mean and standard deviation of 3 determinations) 
 
Solutions % ES 
(w/v) 
% ERS  
(w/v) 
% drug 
 (w/v) 
Conductivity 
 (µs cm-1) 
Viscosity 
(cP) 
F1 0.25 1.00 0.75 44.1±0.2 27.2±0.1 
F2 0.21 0.85 0.94 30.8±0.3 24.8±0.1 
F3 0.18 0.73 1.09 26.4±0.2 25.1±0.0 
F4 0.75 0.50 0.75 29.1±0.1 24.9±0.2 
F5 0.64 0.42 0.94 23.5±0.1 25.4±0.0 
F6 0.55 0.36 1.09 18.5±0.0 24.7±0.1 
F7 1.25 0.00 0.75 14.0±0.1 25.3±0.1 
F8 1.06 0.00 0.94 11.3±0.0 24.5±0.0 
F9 0.91 0.00 1.09 11.0±0.1 24.8±0.0 
 
